ENTRY       D11416                      Drug
NAME        Naxitamab (USAN);
            Naxitamab-gqgk;
            Danyelza (TN)
PRODUCT     DANYELZA (Y-mAbs Therapeutics)
FORMULA     C6414H9910N1718O1996S44
EXACT_MASS  144345.4479
MOL_WEIGHT  144434.4882
SEQUENCE    (Heavy chain)
            QVQLVESGPG VVQPGRSLRI SCAVSGFSVT NYGVHWVRQP PGKGLEWLGV IWAGGITNYN
            SAFMSRLTIS KDNSKNTVYL QMNSLRAEDT AMYYCASRGG HYGYALDYWG QGTLVTVSSA
            STKGPSVFPL APSSKSTSGG TAALGCLVKD YFPEPVTVSW NSGALTSGVH TFPAVLQSSG
            LYSLSSVVTV PSSSLGTQTY ICNVNHKPSN TKVDKRVEPK SCDKTHTCPP CPAPELLGGP
            SVFLFPPKPK DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS
            TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV YTLPPSRDEL
            TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL DSDGSFFLYS KLTVDKSRWQ
            QGNVFSCSVM HEALHNHYTQ KSLSLSPGK
            (Light chain)
            EIVMTQTPAT LSVSAGERVT ITCKASQSVS NDVTWYQQKP GQAPRLLIYS ASNRYSGVPA
            RFSGSGYGTE FTFTISSVQS EDFAVYFCQQ DYSSFGQGTK LEIKRTVAAP SVFIFPPSDE
            QLKSGTASVV CLLNNFYPRE AKVQWKVDNA LQSGNSQESV TEQDSKDSTY SLSSTLTLSK
            ADYEKHKVYA CEVTHQGLSS PVTKSFNRGE C
            (Disulfide bridge: H22-H95, H146-H202, H222-L211, H228-H'228, H231-H'231, H263-H323, H369-H427, H'22-H'95, H'146-H'202, H'222-L'211, H'263-H'323, H'369-H'427, L23-L88, L131-L191, L'23-L'88, L'131-L'191)
  TYPE      Peptide
REMARK      ATC code: L01FX21
            Product: D11416<US>
EFFICACY    Antineoplastic, Anti-GD2 antibody
  DISEASE   Neuroblastoma [DS:H00043]
  TYPE      Monoclonal antibody
TARGET      GD2 [GL:G00114]
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L01 ANTINEOPLASTIC AGENTS
               L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
                L01FX Other monoclonal antibodies and antibody drug conjugates
                 L01FX21 Naxitamab
                  D11416  Naxitamab (USAN) &lt;US&gt;
            USP drug classification [BR:br08302]
             Antineoplastics
              Monoclonal Antibody/Antibody-Drug Conjugate
               Naxitamab
                D11416  Naxitamab (USAN)
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D11416
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D11416
DBLINKS     CAS: 1879925-92-4
            PubChem: 384585393
///
